Forskningssamverkan –olika modeller Stockholm, May 23 2017 Amy Leval, Outcomes Research Manager, Med Dr Epidemiologi, Janssen

Interactive Visualization - Visualizing Prostate Cancer Testing and Outcomes -

Video link

Who are we? Olof Akre Markus Aly Sandra Eloranta Amy Leval Urologist Professor KI olof.akre@ki.se Markus Aly Urologist, Ph.D. Karolinska University Hospital Markus.Aly@ki.se Sandra Eloranta Researcher Med. Sci. KI sandra.eloranta@ki.se Amy Leval Researcher Janssen aleval@ITS.JNJ.com Johan Liwing RWE Partnerships Janssen jliwing@its.jnj.com Mario Romero Visualization Professor KTH marior@kth.se To be continued…

From collaborative visualization to collaborative analytics

OHDSI community •>140 researcher institutions in academia, industry, government, health systems • Common data model (OMOP) •>20 countries •>660 million patients

Collaborative analytics – current possibility, future standard? 11 data sources, 4 countries, 250 million patients Common data modell. Dela på protokoll, analysresultat, inte på individdata!

Yet another way to collaborate….

Janssen’s global real world evidence network By analyzing a broader range of parameters, real world evidence research can uncover outcomes, unmet needs and clues to future medical breakthroughs. Janssen is partnering with top institutions world wide to accelerate this new line of research. Our network aims to: Apply scientific best practices Advance methodologies Generate evidence about disease pathways, healthcare delivery, and the effects of medical interventions Support medical decisions and identify new medical breakthroughs Sweden Canada Hungary USA Korea Taiwan By forming a global real world evidence network, Janssen is taking an industry leading initiative to accelerate real world evidence research. Real World Evidence research is based on studying healthcare data to identify outcomes, cost of care, unmet needs, and potential ways to improve treatment. Adding other parameters such as socio-economic data and data from Randomized Clinical Trials, research can reveal even more information that is useful in healthcare decision making and development of new therapeutic solutions. This is an emerging field of research with great potential. At this point, it is important to improve methodology, sourcing of data and to produce scientific results that can be put into practice. Janssen’s global research network enables a joint and collaborative approach to further advanced real world evidence research. Collaborations in Sweden with Karolinska Institutet. In Canada with University of Alberta. In the US with Optum and UPENN. In Hungary, Korea and Taiwan with national data sources.

Unique opportunity for Nordic life science Real world evidence will impact all phases of medical research and therapeutic development. Thanks to its data infrastructure, the Nordic region can become a hot-spot for advanced medical research by enabling uniquely comprehensive and long term studies. Janssen is partnering with Karolinska Institutet in a major collaborative research initiative that focuses on: Treatment resistant depression Prostate cancer Psoriasis B-Cell malignancies Methodology development Janssen’s real world evidence network also facilitates collaboration in other disease areas, across Nordic institutions. As we learn more and more about how to use real world evidence, it will gradually play a bigger role in how we conduct medical research and develop new therapeutic solutions. Opportunity for Nordic life science The Nordic region has unique registries (thanks to identification numbers; it’s possible to link several parameters, over long time periods) The Nordic region has a research tradition in Real World Evidence, currently producing a major portion of all global research The research produced today mostly focus on registry research – there’s a potential to develop Nordic research into advanced Real World Evidence research that integrate a larger number of data sources. Nordic research could in the future offer unique opportunities to study a complex series of data over long periods of time. Our collaboration with Karolinska Institutet is based on advanced Real World Evidence research Initial 3-year program with joint research team Will initially focus on (see slide) Some of the unique features are: integrate Janssen’s clinical data (YODA) and observational data from multiple Janssen sources to investigate and benchmark against Swedish sources – this collaborative combined data and research collaboration will enable unique insights that either party could not achieve on its own. We are looking for new and extended partnerships in the Nordic region We have a long history of data research in the Nordics. + 10 years collaborating with Karolinska Institutet. Approx. 100 research partnerships in the Nordics covering almost all therapeutic areas. Our global Real World Evidence Network enable us to initiate new partnerships and we are happy to embrace Nordic institutions in our global Real World Evidence Network. 10% Of all global real world evidence research originates from Sweden. Other Nordic countries are also generating an extensive proportion.

Broad collaboration: Johnson & Johnson Innovation + Karolinska Institutet Launched 22 May 2015 A broad and unique industry-academia collaboration in the Nordic region to: advance medical research nurture emerging healthcare companies accelerate development of breakthrough products for improved treatment outcomes To support the collaboration Johnson & Johnson Innovation opened a life science innovation office at Karolinska Institutet. Commercial knowledge Resources Coaching Investment Seed-financing Innovation focus (KI Innovations AB) Abundance of early-stage science World class life sciences research Nordic influence Academic excellence Prestige History

“IMI is the world's biggest public-private partnership (PPP) in the life sciences. Through the IMI 2 programme, it has a €3.3 billion budget for the period 2014-2024.”

IMI’s Big Data for Better Outcomes (BD4BO)

Samverkan – topp 3 checklista 1.Förståelse kring den vetenskapliga frågeställningen 2.Uppskatta kompetens hos olika team - ta in mer extern kompetens vid behov… 3.Kontrakt, och tid för kontrakt och process

Samverkan för att utveckla life science Det finns flera modeller